For use in osteoporosis in post-menopausal women.
Established osteoporosis should have been diagnosed by the following parameters:
For this indication, competent medicine agencies globally authorize below treatments:
50 - 50 mg
From 50 To 50 mg once every 21 day(s)
Post-menopausal women: 50mg every three weeks.
The duration of treatment depends on the clinical response and the possible occurrence of side-effects.
We would recommend that the effectiveness of therapy be monitored with the appropriate methods for osteoporosis on a 6-12 monthly basis.
It should be administered by deep intramuscular injection.